Epizyme Inc. (NASDAQ:EPZM) has been assigned an average rating of “Buy” from the ten analysts that are currently covering the stock. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.80.

A number of research analysts have recently commented on the company. Zacks Investment Research raised Epizyme from a “sell” rating to a “hold” rating in a research note on Wednesday, August 10th. JMP Securities reaffirmed a “buy” rating on shares of Epizyme in a research note on Sunday, November 6th. Leerink Swann reaffirmed an “outperform” rating on shares of Epizyme in a research note on Friday, October 7th. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Epizyme in a research note on Friday, November 4th. Finally, HC Wainwright reissued a “buy” rating on shares of Epizyme in a research note on Sunday, November 6th.

Hedge funds have recently made changes to their positions in the stock. BlackRock Group LTD boosted its stake in shares of Epizyme by 3.7% in the third quarter. BlackRock Group LTD now owns 10,374 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 371 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Epizyme during the second quarter valued at approximately $104,000. HBK Investments L P acquired a new stake in shares of Epizyme during the first quarter valued at approximately $149,000. State Board of Administration of Florida Retirement System raised its stake in shares of Epizyme by 15.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,347 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,102 shares in the last quarter. Finally, BlackRock Advisors LLC raised its stake in shares of Epizyme by 12.5% in the third quarter. BlackRock Advisors LLC now owns 21,244 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 2,365 shares in the last quarter. 80.89% of the stock is currently owned by institutional investors and hedge funds.

Epizyme (NASDAQ:EPZM) opened at 10.50 on Tuesday. The firm’s 50-day moving average price is $9.64 and its 200-day moving average price is $9.72. The stock’s market cap is $609.12 million. Epizyme has a 52 week low of $7.02 and a 52 week high of $18.29.

Epizyme (NASDAQ:EPZM) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.18. The firm had revenue of $6.60 million for the quarter. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. Equities analysts predict that Epizyme will post ($1.98) earnings per share for the current fiscal year.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

5 Day Chart for NASDAQ:EPZM

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.